Drazner M H, Rame J E, Stevenson L W, Dries D L
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75390-9034, USA.
N Engl J Med. 2001 Aug 23;345(8):574-81. doi: 10.1056/NEJMoa010641.
The independent prognostic value of elevated jugular venous pressure or a third heart sound in patients with heart failure is not well established.
We performed a retrospective analysis of the Studies of Left Ventricular Dysfunction treatment trial, in which 2569 patients with symptomatic heart failure or a history of it were randomly assigned to receive enalapril or placebo. The mean (+/-SD) follow-up was 32+/-15 months. The presence of elevated jugular venous pressure or a third heart sound was ascertained by physical examination on entry into the trial. The risks of hospitalization for heart failure and progression of heart failure as defined by death from pump failure and the composite end point of death or hospitalization for heart failure were compared in patients with these findings on physical examination and patients without these findings.
Data on 2479 patients were complete and analyzed. In multivariate analyses that were adjusted for other markers of the severity of heart failure, elevated jugular venous pressure was associated with an increased risk of hospitalization for heart failure (relative risk, 1.32; 95 percent confidence interval, 1.08 to 1.62; P<0.01), death or hospitalization for heart failure (relative risk, 1.30; 95 percent confidence interval, 1.11 to 1.53; P<0.005), and death from pump failure (relative risk, 1.37; 95 percent confidence interval, 1.07 to 1.75; P<0.05). The presence of a third heart sound was associated with similarly increased risks of these outcomes.
In patients with heart failure, elevated jugular venous pressure and a third heart sound are each independently associated with adverse outcomes, including progression of heart failure. Clinical assessment for these findings is currently feasible and clinically meaningful.
颈静脉压升高或第三心音在心力衰竭患者中的独立预后价值尚未明确。
我们对左心室功能障碍研究治疗试验进行了回顾性分析,该试验中2569例有症状心力衰竭或有心力衰竭病史的患者被随机分配接受依那普利或安慰剂治疗。平均(±标准差)随访时间为32±15个月。在进入试验时通过体格检查确定是否存在颈静脉压升高或第三心音。比较体格检查有这些发现的患者和无这些发现的患者发生心力衰竭住院和心力衰竭进展(定义为泵衰竭死亡)以及死亡或心力衰竭住院复合终点的风险。
2479例患者的数据完整并进行了分析。在针对心力衰竭严重程度的其他标志物进行校正的多变量分析中,颈静脉压升高与心力衰竭住院风险增加相关(相对风险,1.32;95%置信区间,1.08至1.62;P<0.01),与死亡或心力衰竭住院风险增加相关(相对风险,1.30;95%置信区间,1.11至1.53;P<0.005),与泵衰竭死亡风险增加相关(相对风险,1.37;95%置信区间,1.07至1.75;P<0.05)。第三心音的存在与这些结局风险的类似增加相关。
在心力衰竭患者中,颈静脉压升高和第三心音各自独立地与不良结局相关,包括心力衰竭进展。目前对这些发现进行临床评估是可行的且具有临床意义。